Mologen AG logo

MGNK - Mologen AG Share Price

€0.105 0.0  4.9%

Last Trade - 11:01am

Micro Cap
Market Cap £1.13m
Enterprise Value £-1.45m
Revenue £74.2k
Position in Universe 1021st / 1042
Unlock MGNK Revenue
Relative Strength (%)
1m +4.24%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -91.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 2019E 2020E CAGR / Avg
0.23 0.012 0.039 0.074 0.047 3.05 0.10 42.5 +68.1%
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2019, Mologen AG revenues decreased 97% to EUR81K. Net loss increased 19% to EUR11M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other operating income decrease of 76% to EUR226K (income), Interest expenses increase of 57% to EUR686K (expense), Depreciation and amortization increase from EUR27K to EUR104K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


MGNK Revenue Unlock MGNK Revenue

Net Income

MGNK Net Income Unlock MGNK Revenue

Normalised EPS

MGNK Normalised EPS Unlock MGNK Revenue

PE Ratio Range

MGNK PE Ratio Range Unlock MGNK Revenue

Dividend Yield Range

MGNK Dividend Yield Range Unlock MGNK Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MGNK EPS Forecasts Unlock MGNK Revenue
Profile Summary

Mologen AG is a Germany-based company engaged in the biotechnology and medical research industry. The Company specializes in the research and development of drugs in the fields of oncology and infectious diseases. The Company develops medicines and vaccines on the basis of its MIDGE, dSLIM and EnanDIM platform technologies and through the use of its human, allogeneic tumor cell bank. Within the area of oncology, the Company develops Lefitolimod, which is intended to enable the patient's immune system to recognize the body's own cancer cells and fight them, MGN1601, which works like a therapeutic vaccination against cancer, as well as MGN1404, which is targeted at malignant melanoma. Within the area of infectious diseases, the Company develops deoxyribonucleic acid (DNA) vaccines against leishmaniasis and hepatitis B.

Last Annual December 31st, 2018
Last Interim September 30th, 2019
Public Since June 18, 1998
No. of Shareholders: n/a
No. of Employees: 43
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange XETRA
Shares in Issue 12,435,774
Free Float (0.0%)
Eligible for
MGNK Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MGNK
Upcoming Events for MGNK
Frequently Asked Questions for Mologen AG
What is the Mologen AG share price?

As of 11:01am, shares in Mologen AG are trading at €0.105, giving the company a market capitalisation of £1.13m. This share price information is delayed by 15 minutes.

How has the Mologen AG share price performed this year?

Shares in Mologen AG are currently trading at €0.105 and the price has moved by -87.94% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Mologen AG price has moved by -86.74% over the past year.

What are the analyst and broker recommendations for Mologen AG?

Of the analysts with advisory recommendations for Mologen AG, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Mologen AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Mologen AG next release its financial results?

Mologen AG is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-09-30
What is the Mologen AG dividend yield?

Mologen AG does not currently pay a dividend.

Does Mologen AG pay a dividend?

Mologen AG does not currently pay a dividend.

When does Mologen AG next pay dividends?

Mologen AG does not currently pay a dividend.

How do I buy Mologen AG shares?

To buy shares in Mologen AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Mologen AG?

Shares in Mologen AG are currently trading at €0.105, giving the company a market capitalisation of £1.13m.

Where are Mologen AG shares listed? Where are Mologen AG shares listed?

Here are the trading details for Mologen AG:

Country of listing: Germany
Exchange: GER
Ticker Symbol: MGNK
What kind of share is Mologen AG?

Based on an overall assessment of its quality, value and momentum, Mologen AG is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Mologen AG share price forecast 2020?

Shares in Mologen AG are currently priced at €0.105. At that level they are trading at 25.2% discount to the analyst consensus target price of 0.00.

Analysts covering Mologen AG currently have a consensus Earnings Per Share (EPS) forecast of -1.3 for the next financial year.

How can I tell whether the Mologen AG share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mologen AG. Over the past six months, the relative strength of its shares against the market has been 1.23%. At the current price of €0.105, shares in Mologen AG are trading at -7.48% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Mologen AG PE Ratio?

We were not able to find PE ratio data for Mologen AG.

Who are the key directors of Mologen AG?

Mologen AG's management team is headed by:

Oliver Krautscheid - CSU
Stefan Manth - CEO
Walter Miller - CFO
Matthias Baumann - EXB
Michael Schultz - SUB
Gerhard Greif - SUB
Friederike Zahm - SUB
Who are the major shareholders of Mologen AG?

Here are the top five shareholders of Mologen AG based on the size of their shareholding:

Wagner (Thorsten) Individual Investor
Percentage owned: 14.41% (1.79m shares)
Adler Capital Partners AG Corporation
Percentage owned: 3.32% (413k shares)
Drabe (Kai) Individual Investor
Percentage owned: 3.25% (404k shares)
Axxion S.A. Investment Advisor
Percentage owned: 2.98% (371k shares)
Signal Iduna Asset Management GmbH Investment Advisor
Percentage owned: 2.24% (279k shares)
Similar to MGNK
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.